“The role of genomic testing in bladder is expanding almost every year,” says Faltas.
Bishoy M. Faltas, MD, assistant professor of Medicine at Weill Cornell Medicine, explains the growing role of genomic testing in bladder cancer, including the emerging understanding of the role of germline alterations.
Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma
April 12th 2023The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.
Rapid genetic testing model found feasible for patients with prostate cancer
March 31st 2023"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
2 Clarke Drive
Cranbury, NJ 08512